Start the program by clicking on the Start Program icon at the bottom of this page.
|
| Program Title |
 |
|
Queries in the Management of Brain Metastases
Release Date: October-09-09
Credit Expiration Date: October-09-10
|
|
|
 |
| Program Developer/Facilitator |
 |
|
Medical Communications Media, Inc. |
|
|
|
| Target Audience |
|
|
| This educational activity is designed to meet the needs of neurosurgeons, neuro-oncologists, radiation oncologists, medical oncologists, and other healthcare providers interested in the treatment of primary gliomas. |
|
|
|
| Credit Hours |
|
|
|
|
|
| Medium |
|
|
|
|
|
| Program Description |
|
|
| GliomaEd.com contains a mechanism that website members can use to submit their neuro-oncology -- related questions to our expert advisory board members. Questions are directed to one of the board’s neuro-oncologists, radiation oncologists, or neurosurgeons, depending on whether the question is focused more on chemotherapy, radiotherapy, or surgery. Subjects revolve around the diagnosis, management, and treatment of various brain tumors. This activity addresses questions related to brain metastases, including radioresistance, the use of antiepileptic drugs, and the utility of chemotherapy. |
|
|
|
| Learning Objectives |
|
|
|
|
|
| Faculty |
|
|
Marc C. Chamberlain, MD
Professor of Neurology
Department of Neurology and Neurosurgery
University of Washington/Fred Hutchinson Cancer Center
Seattle, Washington, USA
|
|
|
|
| Disclosures |
|
|
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Dr. Chamberlain discloses product consultation and speakers’ bureau participation for Schering-Plough and Genentech.
|
|
|
|
| Commercial Support Statements |
|
|
This activity is supported by an educational grant from Schering-Plough Corporation. |
|
|
|
|
|
| Credit Statements |
|
|
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Inc. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
|
|
|
|
|
|
| Instructions |
|
|
|
|
|
| Certificate Fee |
|
|
|
|
|
| Disclaimer |
|
|
| © 2009. All rights reserved. None of the contents of this publication may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this publication are those of the faculty members and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or Schering-Plough. Any medications, diagnostic procedures, or treatments discussed by the faculty members should not be used by clinicians or other healthcare professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities. |
|
|
| |
